ZURICH, Switzerland & PHILADELPHIA, PA & COPENHAGEN, Denmark — InterAx Biotech Ltd and Alveus Therapeutics Inc. said they have entered a strategic research collaboration and licensing agreement to develop a differentiated small-molecule treatment for metabolic disease, targeting durable weight loss with improved tolerability.
The partnership establishes a joint research program focused on a target and therapeutic modality of long-standing but largely untapped interest in metabolic medicine. The companies said the effort will combine InterAx’s Deep Signal platform, designed to optimize drug candidates for specific cellular signaling profiles, with Alveus’s research and development expertise in obesity, diabetes, and cardiometabolic disease.
Financial terms were not disclosed. The agreement includes an upfront payment to InterAx and the potential for additional development, regulatory, and commercial milestone payments as the program advances.
“We are thrilled to join forces with Alveus to advance a highly differentiated therapeutic candidate designed to overcome the limitations of today’s obesity medications,” said Andrew Roberts, chief executive officer of InterAx. He said the company’s Deep Signal platform is built to address the complexity of G protein-coupled receptor signaling, an area central to many metabolic pathways.
Alveus officials said the collaboration aligns with the company’s strategy to pursue next-generation metabolic therapies that can deliver sustained benefits while reducing side effects seen with current treatments.
“InterAx’s unique platform integrates drug chemistry, protein structure, cellular signaling, and therapeutic efficacy,” said Jacob Jeppesen, chief scientific officer and head of research and development at Alveus. “We are excited to apply this approach to our joint program efforts.”
The deal comes as pharmaceutical and biotechnology companies intensify efforts to develop new obesity and metabolic disease treatments amid soaring global demand and growing scrutiny of long-term safety and tolerability in existing therapies.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.